Skip to content

Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities

Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities Written for FDA Approved Medications for Osteoporosis Treatment.

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00280943
Enrollment
64
Registered
2006-01-24
Start date
2005-01-31
Completion date
2007-03-31
Last updated
2023-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fractures, Osteoporosis

Keywords

All NC LTC facilities having ten residents with a hip fracture or osteoporosis on the MDS will be invited to participate in the trial

Brief summary

Osteoporotic fractures of the hip are a major cause of admission to long-term care facilities. Such fractures put patients at high risk for further fractures, pain and disability. Current data show that many patients in long-term care facilities do not receive FDA medications for their osteoporosis. This trial will test whether a multi-model intervention (which provides feedback about provider use of osteoporosis medications, information about osteoporosis, and currently approved osteoporosis medications)directed at physicians, other health care providers, and nurses will improve the number of prescriptions written for FDA approved medications for osteoporosis treatment.

Interventions

BEHAVIORALLong-term care facilities in the intervention arm will receive education and feedback audit on performance

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Any North Carolina long-term care facility with ten residents who had had a hip fracture or osteoporosis diagnosis

Design outcomes

Primary

MeasureTime frame
Number of new prescriptions for FDA-Approved osteoporosis medications.

Secondary

MeasureTime frame
Secondary Outcome Measures: Changes in number of bone mineral density test ordered, change in the number of hip protectors issued, change in the number of prescriptions for calcium and vitamin D, changes in the rate of new osteoporotic fractures.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026